Journal
CRITICAL CARE CLINICS
Volume 27, Issue 3, Pages 525-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccc.2011.04.005
Keywords
ALI; ARDS; Surfactant; Lungs
Categories
Funding
- NIH [HL-1020113, HL094641]
Ask authors/readers for more resources
This article examines exogenous lung surfactant replacement therapy and its usefulness in mitigating clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Surfactant therapy is beneficial in term infants with pneumonia and meconium aspiration lung injury, and in children up to age 21 years with direct pulmonary forms of ALI/ARDS. However, extension of exogenous surfactant therapy to adults with respiratory failure and clinical ALI/ARDS remains a challenge. This article reviews clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS, focusing on its potential advantages in patients with direct pulmonary forms of these syndromes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available